Clinical Trial

Efficacy and Safety of SR1375 in Adult Patients With CAP

Study acronym: CAP
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-27; most recent amendment 2025-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-02-08
Trial Details
NCT Number NCT06577558
Lead Sponsor Shanghai SIMR Biotechnology Co., Ltd.
Conditions Community-acquired Pneumonia
Enrollment 240 participants
Start Date 2024-09-10
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-09